Benchmark Cuts Humacyte (NASDAQ:HUMA) Price Target to $10.00

by · The Cerbat Gem

Humacyte (NASDAQ:HUMA – Get Free Report) had its price target reduced by investment analysts at Benchmark from $11.00 to $10.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock.

A number of other brokerages have also issued reports on HUMA. BTIG Research restated a “buy” rating and issued a $6.00 price target on shares of Humacyte in a research note on Friday, November 21st. HC Wainwright reissued a “buy” rating and set a $3.00 price objective on shares of Humacyte in a report on Monday, December 1st. Wall Street Zen lowered shares of Humacyte from a “hold” rating to a “sell” rating in a research note on Sunday, December 21st. D. Boral Capital reiterated a “buy” rating and issued a $25.00 price target on shares of Humacyte in a research note on Monday, January 5th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Humacyte in a research note on Monday, December 29th. Seven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $8.14.

Read Our Latest Stock Analysis on HUMA

Humacyte Stock Up 1.5%

Shares of NASDAQ HUMA traded up $0.02 during midday trading on Wednesday, reaching $1.04. 1,733,105 shares of the company’s stock were exchanged, compared to its average volume of 4,547,753. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.90 and a current ratio of 1.62. Humacyte has a 52-week low of $0.91 and a 52-week high of $4.85. The business’s fifty day moving average price is $1.17 and its two-hundred day moving average price is $1.61. The stock has a market capitalization of $193.82 million, a PE ratio of -4.50 and a beta of 1.93.

Humacyte (NASDAQ:HUMA – Get Free Report) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.03. The business had revenue of $0.75 million for the quarter, compared to analyst estimates of $0.92 million. Analysts forecast that Humacyte will post -1.27 EPS for the current year.

Institutional Investors Weigh In On Humacyte

Several large investors have recently added to or reduced their stakes in the stock. Marshall Wace LLP lifted its stake in Humacyte by 5,308.2% in the second quarter. Marshall Wace LLP now owns 2,639,194 shares of the company’s stock valued at $5,516,000 after buying an additional 2,590,394 shares during the last quarter. CenterBook Partners LP increased its holdings in shares of Humacyte by 141.1% in the 2nd quarter. CenterBook Partners LP now owns 3,430,255 shares of the company’s stock worth $7,169,000 after acquiring an additional 2,007,743 shares during the period. Geode Capital Management LLC lifted its position in Humacyte by 33.4% in the 2nd quarter. Geode Capital Management LLC now owns 2,948,508 shares of the company’s stock valued at $6,163,000 after purchasing an additional 738,142 shares during the last quarter. Vanguard Group Inc. lifted its position in Humacyte by 7.4% in the 3rd quarter. Vanguard Group Inc. now owns 7,520,055 shares of the company’s stock valued at $13,085,000 after purchasing an additional 520,431 shares during the last quarter. Finally, Clough Capital Partners L P acquired a new position in Humacyte during the 2nd quarter valued at about $504,000. 44.71% of the stock is owned by institutional investors and hedge funds.

About Humacyte

(Get Free Report)

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.

Recommended Stories